Effects of lutein supplementation on inflammatory biomarkers and metabolic risk factors in adults with central obesity: study protocol for a randomized controlled study
Background: The prevalence of central obesity is increasing consistently, and visceral fat is associated with increased production of inflammatory factors and metabolic risk factors. Lutein might retard the development of metabolic disease through its antioxidant and anti-inflammatory properties. Furthermore, epidemiological studies have associated higher dietary intake and serum levels of lutein with decreased adiposity. However, few randomized controlled trials (RCTs) have shown the effects of lutein supplementation on inflammatory biomarkers and metabolic risk factors, especially in adults with central obesity.
Methods: This study will be conducted as a double-blinded, parallel placebo-controlled clinical trial in which 120 people with central obesity aged 18-60 years old and willing to provide informed consent will be randomly assigned to the intervention or placebo group in a 1:1 ratio according to sex, age and waist circumference. The intervention group will receive 10 mg daily lutein supplementation for 12 weeks to explore the effect of lutein supplementation on serum lutein, glycaemic and lipid profiles, inflammatory factors and body composition. Two populations (intention-to-treat population and per-protocol population) will be used in the data analyses.
Discussion: Our findings from this trial will contribute to the knowledge of the association between lutein supplementation and inflammatory biomarkers and metabolic risk factors in people with central obesity, which will offer a possibility for the prevention of inflammatory diseases.
Figure 1
This is a list of supplementary files associated with this preprint. Click to download.
Posted 19 Dec, 2019
On 06 Jan, 2020
On 14 Dec, 2019
On 13 Dec, 2019
On 12 Dec, 2019
On 10 Dec, 2019
On 09 Dec, 2019
On 09 Dec, 2019
Invitations sent on 13 Nov, 2019
On 13 Nov, 2019
Received 13 Nov, 2019
On 13 Nov, 2019
On 12 Nov, 2019
On 12 Aug, 2019
On 11 Aug, 2019
Effects of lutein supplementation on inflammatory biomarkers and metabolic risk factors in adults with central obesity: study protocol for a randomized controlled study
Posted 19 Dec, 2019
On 06 Jan, 2020
On 14 Dec, 2019
On 13 Dec, 2019
On 12 Dec, 2019
On 10 Dec, 2019
On 09 Dec, 2019
On 09 Dec, 2019
Invitations sent on 13 Nov, 2019
On 13 Nov, 2019
Received 13 Nov, 2019
On 13 Nov, 2019
On 12 Nov, 2019
On 12 Aug, 2019
On 11 Aug, 2019
Background: The prevalence of central obesity is increasing consistently, and visceral fat is associated with increased production of inflammatory factors and metabolic risk factors. Lutein might retard the development of metabolic disease through its antioxidant and anti-inflammatory properties. Furthermore, epidemiological studies have associated higher dietary intake and serum levels of lutein with decreased adiposity. However, few randomized controlled trials (RCTs) have shown the effects of lutein supplementation on inflammatory biomarkers and metabolic risk factors, especially in adults with central obesity.
Methods: This study will be conducted as a double-blinded, parallel placebo-controlled clinical trial in which 120 people with central obesity aged 18-60 years old and willing to provide informed consent will be randomly assigned to the intervention or placebo group in a 1:1 ratio according to sex, age and waist circumference. The intervention group will receive 10 mg daily lutein supplementation for 12 weeks to explore the effect of lutein supplementation on serum lutein, glycaemic and lipid profiles, inflammatory factors and body composition. Two populations (intention-to-treat population and per-protocol population) will be used in the data analyses.
Discussion: Our findings from this trial will contribute to the knowledge of the association between lutein supplementation and inflammatory biomarkers and metabolic risk factors in people with central obesity, which will offer a possibility for the prevention of inflammatory diseases.
Figure 1